Arrhythmias & electrophysiology
Association of Antiarrhythmic Drug Therapy With Syncope and Pacemaker Implantation in Patients With Atrial Fibrillation
Authors' conclusion
This study showed an association between AADs and risk of pacemaker implantation or syncope, a consistent finding across various subgroups.
Study context
- Population
- Patients with new-onset Atrial Fibrillation (AF), Korean National Health Insurance Service, 2013–2019
- Participants
- 770,977 new-onset AF cases
- Exposure
- AAD users vs nonusers
- AAD usersn = 142,141
- Outcome
- Pacemaker implantation or syncope
Methodological detailsnationwide claims database, propensity-score matched analysis
- Nationwide claims database
- Propensity-score matched analysis
Main finding
As reported in the abstract
AAD use associated with increased risk of pacemaker implantation or syncope (multivariate-adjusted)
3.5-fold
AAD use associated with increased risk of syncope
2.0-fold
AAD use associated with increased risk of pacemaker implantation
5.0-fold
Observational data: associations, not effects.
Further findings
Pacemaker implantation or syncope, propensity-score matched analysis
- Similar results; significant association between AAD use and risk
Pacemaker implantation or syncope, subgroups
- Association consistent across various subgroups
- Women more susceptible to adverse effects of AADs than men
Original publication
Association of Antiarrhythmic Drug Therapy With Syncope and Pacemaker Implantation in Patients With Atrial Fibrillation. J Am Coll Cardiol. Published 19 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →